Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

🇺🇸 Seeking Alpha (US) — 2026-09-28

The transcript discusses topline results from the Phase III AZURE-1 study of brelovitug for chronic hepatitis delta. It concerns clinical-trial findings and treatment development for a serious liver infection.

Markets Health Mirum Pharmaceuticals brelovitug AZURE-1 Phase III hepatitis delta clinical trial

Read original source →

Bose starts adding Auracast to its headphones
The Verge — 2026-09-28
An Inversion of the US Yield Curve Becomes New Risk As Fed Hikes
Bloomberg — 2026-09-28
MongoDB: Selloff Is Overdone, But The Stock Still Isn't Cheap
Seeking Alpha — 2026-09-28
Tesla delays Roadster 2 event again due to bad weather
TechCrunch — 2026-09-28
Renovus Capital’s TJP acquires life sciences market researcher Evolution Consulting & Research
PE Hub — 2026-09-28
Brixmor Property Group Inc. (BRX) M&A Call Transcript
Seeking Alpha — 2026-09-28

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

AI Summary

Related Articles

Bose starts adding Auracast to its headphones

An Inversion of the US Yield Curve Becomes New Risk As Fed Hikes

MongoDB: Selloff Is Overdone, But The Stock Still Isn't Cheap

Tesla delays Roadster 2 event again due to bad weather

Renovus Capital’s TJP acquires life sciences market researcher Evolution Consulting & Research

Brixmor Property Group Inc. (BRX) M&A Call Transcript